stockportfolio.pro
Stocks / DXCM vs NTRA
DXCM vs NTRA
DexCom, Inc. and Natera, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
| DexCom, Inc. (DXCM) | Natera, Inc. (NTRA) | |
|---|---|---|
| Market cap | $30.2B | $31.0B |
| Revenue (latest FY) | $4.66B | $2.31B |
| Net income (latest FY) | $836.30M | $-208.16M |
| Revenue growth (5y CAGR) | 19.3% | 42.6% |
| Net margin | 17.9% | -9.0% |
| Return on equity | 30.5% | -12.2% |
| P/E ratio | 32.9 | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 7 | 0 |
| Positive free cash flow | Yes | Yes |
Compare them properly — statement by statement
Open either company interactively: 19 years of income statement, balance sheet and cash flow, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open DXCM — free Open NTRA — freeFrequently asked questions
Which is bigger, DXCM or NTRA?
Natera, Inc. is larger by market capitalization — $31.0B versus $30.2B.
Which grows faster, DXCM or NTRA?
Over the last five fiscal years, Natera, Inc. grew revenue faster — 42.6%/yr versus 19.3%/yr, computed from SEC-filed statements.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.